Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
It has been shown that many patients with lymphoma or chronic lymphocytic leukemia (CLL)have
low levels of complement. Several drugs have been approved by the Food and Drug
Administration (FDA) for use in this cancer. However, these drugs are often used as
combination therapies which means two or more drugs are part of the treatment. Many people,
especially elderly patients, cannot put up with the use of multiple drugs because of the side
effects.
The main purpose of this study is to see if patients respond to therapy with human plasma
(known as fresh frozen plasma or FFP) and ofatumumab. Another purpose of the study is to find
out if this therapy will increase chances of getting rid of leukemia. This study will also
look at the levels of complement in your blood. The levels of complement may allow better
understanding of whether increasing the levels of complement by giving FFP may help control
leukemia.